LONDON, May 7, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Advaxis Inc. (NASDAQ: ADXS), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on Vertex Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Vertex%20Pharma&d=07-May-2015&s=VRTX. On Wednesday, May 06, 2015, the NASDAQ Composite ended at 4,919.65, down 0.40%, the Dow Jones Industrial Average declined 0.48%, to finish the day at 17,841.98, and the S&P 500 closed at 2,080.15, down 0.45%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 831.07, down 0.48%, while the index has advanced 3.01% in the previous three months. Register for your complimentary reports at the links given below.

Vertex Pharmaceuticals Inc.'s stock finished Wednesday's session 0.64% higher at $122.93. A total of 1.27 million shares were traded, which was below its three months average volume of 1.62 million shares. The stock moved between $121.38 and $125.16 during the session. Over the last one month and the previous three months, Vertex Pharmaceuticals Inc.'s shares have gained 3.96% and 13.13%, respectively. Additionally, from the beginning of 2015, the stock has advanced 3.48%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $124.70 is greater than its 200-day moving average of $111.86. Vertex Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 43.83. Sign up and read the free notes on VRTX at:

http://get.Investor-Edge.com/pdf/?c=Vertex%20Pharma&d=07-May-2015&s=VRTX

On Wednesday, shares in Advaxis Inc. fluctuated between $17.40 and $18.80 before ending the session 6.23% higher at $18.76. The stock reported a trading volume of 0.91 million shares, below its three months average volume of 1.48 million shares. Advaxis Inc.'s shares have rallied 16.45% in the last one month, 149.14% in the previous three months and 134.21% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $15.35 and $7.45, respectively. Moreover, shares of Advaxis Inc. have an RSI of 48.26. The complimentary notes on ADXS can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Advaxis&d=07-May-2015&s=ADXS

Merrimack Pharmaceuticals Inc.'s stock lost 1.75%, to close the day at $11.22. The stock recorded a trading volume of 1.43 million shares, above its three months average volume of 1.36 million shares. The stock oscillated between $11.05 and $11.89 during the session. Over the last three trading sessions and since the start of this year, Merrimack Pharmaceuticals Inc.'s shares have declined 5.87% and 0.71%, respectively. However, the stock has surged 26.49% in the previous three months. The company is trading above its 200-day moving average of $9.49, while the 200-day moving average is below Merrimack Pharmaceuticals Inc.'s 50-day moving average of $12.00. Additionally, the stock has an RSI of 41.92. Register for free on Investor-Edge and access the latest research on MACK at:

http://get.Investor-Edge.com/pdf/?c=Merrimack%20Pharma&d=07-May-2015&s=MACK

On Wednesday, shares in Tekmira Pharmaceuticals Corp. recorded a trading volume of 0.66 million shares, lower than its three months average volume of 0.73 million shares. The stock ended the day at $14.42, which was 1.41% above its previous day's closing of $14.22, and registered an intraday range of $14.01 and $14.55. Tekmira Pharmaceuticals Corp.'s shares have lost 1.70% in the previous three trading sessions, 15.52% in the last one month and 4.82% on YTD basis. The company is trading below its 50-day and 200-day moving averages of $18.06 and $18.39, respectively. Furthermore, shares of Tekmira Pharmaceuticals Corp. have an RSI of 25.13. The complete research on TKMR is available for free at:

http://get.Investor-Edge.com/pdf/?c=Tekmira%20Pharma&d=07-May-2015&s=TKMR

United Therapeutics Corp.'s stock declined 1.02%, to close Wednesday's session at $168.02, after oscillating between $166.00 and $173.36. The stock recorded a trading volume of 0.55 million shares, below its three months average volume of 0.69 million shares. Over the last three months and since the beginning of 2015, United Therapeutics Corp.'s shares have surged 18.40% and 29.76%, respectively. However, the stock has lost 1.70% in the previous three trading sessions. The company is trading above its 200-day moving average. The stock's 50-day moving average of $172.47 is above its 200-day moving average of $136.24. Furthermore, United Therapeutics Corp.'s stock traded at a PE ratio of 49.71 and has an RSI of 44.38. Free in depth research on UTHR is available at:

http://get.Investor-Edge.com/pdf/?c=United%20Therapeutics&d=07-May-2015&s=UTHR

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge